Literature DB >> 25976674

The anti-hypertensive drug reserpine induces neuronal cell death through inhibition of autophagic flux.

Kang Il Lee1, Min Ju Kim2, Hyongjong Koh2, Jin I Lee1, Sim Namkoong1, Won Keun Oh3, Junsoo Park4.   

Abstract

Reserpine is a well-known medicine for the treatment of hypertension and schizophrenia, but its administration can induce Parkinson's disease (PD)-like symptoms in humans and animals. Reserpine inhibits the vesicular transporter of monoamines and depletes the brain of monoamines such as dopamine. However, the cellular function of reserpine is not fully understood. In this report, we present one possible mechanism by which reserpine may contribute to PD-like symptoms. Reserpine treatment induced the formation of enlarged autophagosomes by inhibiting the autophagic flux and led to accumulation of p62, an autophagy adapter molecule. In particular, reserpine treatment increased the level of α-synuclein protein and led to accumulation of α-synuclein in autophagosomes. Treatment with rapamycin enhanced the effect of reserpine by further increasing the level of α-synuclein and neuronal cell death. Drosophila raised on media containing reserpine showed loss of dopaminergic neurons. Furthermore, cotreatment with reserpine and rapamycin aggravated the loss of dopaminergic neurons. Our results suggest that reserpine contributes to the loss of dopaminergic neurons by interfering with autophagic flux.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autophagic flux; Autophagy; Parkinson's disease; Reserpine; α-Synuclein

Mesh:

Substances:

Year:  2015        PMID: 25976674     DOI: 10.1016/j.bbrc.2015.04.145

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection.

Authors:  Subhajit Maity; Abhik Saha
Journal:  Front Microbiol       Date:  2021-05-14       Impact factor: 5.640

2.  Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression.

Authors:  Anderson H F F Leão; Ywlliane S R Meurer; Anatildes F da Silva; André M Medeiros; Clarissa L C Campêlo; Vanessa C Abílio; Rovena C G K Engelberth; Jeferson S Cavalcante; Geison S Izídio; Alessandra M Ribeiro; Regina H Silva
Journal:  Front Aging Neurosci       Date:  2017-03-27       Impact factor: 5.750

Review 3.  Canonical and Noncanonical Autophagy as Potential Targets for COVID-19.

Authors:  Melissa Bello-Perez; Isabel Sola; Beatriz Novoa; Daniel J Klionsky; Alberto Falco
Journal:  Cells       Date:  2020-07-05       Impact factor: 6.600

4.  Autophagy Activation Is Involved in Acidic Fibroblast Growth Factor Ameliorating Parkinson's Disease via Regulating Tribbles Homologue 3.

Authors:  Xingfeng Zhong; Beini Wang; Guanyinsheng Zhang; Yuan Yuan; Xiaoli Hu; Jun Xiong; Peipei Zheng; Yaqian Liu; Ke Xu; Jian Xiao; Yanqing Wu; Junming Ye
Journal:  Front Pharmacol       Date:  2019-12-02       Impact factor: 5.810

5.  Neuroinflammation in early, late and recovery stages in a progressive parkinsonism model in rats.

Authors:  Debora M G Cunha; Marcela Becegato; Ywlliane S R Meurer; Alvaro C Lima; Narriman Gonçalves; Vinícius S Bioni; Sheila A Engi; Paula C Bianchi; Fabio C Cruz; Jose R Santos; Regina H Silva
Journal:  Front Neurosci       Date:  2022-08-26       Impact factor: 5.152

6.  Conessine Interferes with Oxidative Stress-Induced C2C12 Myoblast Cell Death through Inhibition of Autophagic Flux.

Authors:  Hyunju Kim; Kang Il Lee; Minsu Jang; Sim Namkoong; Rackhyun Park; Hyunwoo Ju; Inho Choi; Won Keun Oh; Junsoo Park
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

7.  2,2'-Methylenebis (6-tert-butyl 4-methylphenol) enhances the antitumor efficacy of belotecan, a derivative of camptothecin, by inducing autophagy.

Authors:  Minsu Jang; Hyunju Kim; Rackhyun Park; Daum Jo; Eun-Ju Lee; Won Keun Oh; Junsoo Park
Journal:  Oncotarget       Date:  2017-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.